Upcoming Webinars

“Using PBPK modeling to assess the impact of diseases on oral drug absorption: a tale of 2 drugs”

Wednesday, June 29, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)

Randomized clinical trial is the most effective way to determine whether a cause-and-effect relationship exists between an intervention and a predefined clinical outcome. Much attention has been paid to the internal validity of a clinical trial, i.e. the extent to which the design and conduct of a trial eliminates the possibility of bias. In this webinar, we will go over two case studies leveraging IVIVE-PBPK modeling to prospect the impact of HIV and cystic fibrosis on the oral absorption of two broadly prescribed BCS 2 drugs.

Dr. Rodrigo Cristofoletti
Assistant Professor, Center for Pharmacometrics & Systems Pharmacology, Dept. of Pharmaceutics
University of Florida

Register Here

“Predicting pharmacokinetics of multisource acyclovir oral products through Physiologically Based Biopharmaceutics Modeling”

Wednesday, July 13, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)

Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity polymorphs of the organic cation transporter (OCT1) in Europeans. This webinar will explore this study in depth.

Dr. Peter Langguth, University Professor at Johannes Gutenberg University Mainz
Dr. Mauricio A. Garcia, PhD student/Research Assistant, Johannes Gutenberg University Mainz

Register Here


Watch Past Webinars

What’s new in MonolixSuite 2021

Watch out for the release of MonolixSuite 2021!


PBPK Modeling Approach in Pregnant Subjects and Fetus

PBPK modeling gives birth to a new application!

Stream Download

Developing a PBPK modeling approach for evaluating drug product performance in infants based on adults data

Understanding drug and drug formulation performance in relation to the prandial conditions is essential for ensuring the safety and efficacy of products to be administered to pediatric patients, especially newborns...

Stream Download

ADMET Predictor® 10.3 (APX.3): Flagship machine learning platform for ADMET modeling

Panelist David Miller, VP of ADMET Cheminformatics will show some of the new features in APX.3, including details about a new REST API for deployment via Web services.

Stream Download

Real-world Considerations in Pharma for QSP Modeling

Quantitative systems pharmacology (QSP) modeling enables better drug development decisions through a more advanced understanding of the disease area of inter

Stream Download

Introducing, IPFsym™ the QSP modeling software for idiopathic pulmonary fibrosis

IPFsym® is a mechanistic, mathematical model for QSP of idiopathic pulmonary fibrosis (IPF) that can be used to predict efficacy for potential treatments.

Stream Download

Culture & Conversation – The accelerator pedal for innovation…

The central idea behind the “learn and confirm” paradigm is to emphasize the learning part of R&D and then intelligently apply what has been learned to the design of clinical trials.

Stream Download

Best Practices for Membrane & Biphasic In Vitro Dissolution with DDDPlus™ & GastroPlus®

DDDPlus is a state-of-the-art simulation platform for in vitro dissolution.

Stream Download

Simulx Webinar: Optimizing Sample Size of a Phase III trial

What if we could reduce the size of a phase III study from 400 to 80 subjects and make it twice as short? Thanks to model-informed clinical trial design, it's possible!


NAFLDsym Application Showcase: Key Examples of NAFLDsym Use within Drug Development

NAFLDsym is a quantitative systems pharmacology (QSP) modeling software to support the development of treatments for non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Stream Download